Landos Biopharma (LABP) PT Lowered to $30 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts LABP Hot Sheet
Rating Summary:
1 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Join SI Premium – FREE
Jefferies analyst Chris Howerton lowered the price target on Landos Biopharma (NASDAQ: LABP) to $30.00 (from $32.00) while maintaining a Buy rating.
The analyst commented, "Following recent leadership transition with new Chairman and interim CEO, Co announced to strategically re-prioritize pipeline optimizing clinical development and capital allocation. As a result, Co expects to be focused on omilancor, NX-13 and LABP-104, and plans to start a Ph2b vs. Ph3 for omilancor in UC and reassess Ph2 powering in CD. We see this a sensible move and update our PT to $30 (vs. prev. $32) to reflect new pipline plan. We maintain Buy rating."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Downgrades Black Hills Corp (BKH) to Hold on Valuation
- Freedom Broker Upgrades Tennant Company (TNC) to Buy
- Freedom Broker Upgrades Chevron (CVX) to Hold
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
